Companies 0 See All

Hedge Funds 0 See All

Insiders 0 See All

Institutional Investors 0 See All

Click here to see all results for

Home > Insider Trading > Filing (0001839516-23-000004)

Filing Details

Accession Number:: 0001839516-23-000004
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2023-03-23 19:48:38
Reporting Period:: 2023-03-21

Accepted Time:: 2023-03-23 19:48:38
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1819790	Tarsus Pharmaceuticals Inc.	TARS	Biological Products, (No Disgnostic Substances) (2836)	814717861

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1839516	C. Dianne Whitfield	C/O Tarsus Pharmaceuticals, Inc. 15440 Laguna Canyon Road, Suite 160 Irvine CA 92618	Chief Human Resources Officer	No	Yes	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Disposition	2023-03-21	326	$12.89	11,897	No	4	S	Direct
Common Stock	Disposition	2023-03-22	333	$12.64	11,564	No	4	S	Direct
Common Stock	Disposition	2023-03-23	345	$12.15	11,219	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct

Footnotes

The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the previously reported vesting and settlement of Restricted Stock Units. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.